Adial Pharmaceuticals adjourns 2026 annual meeting again over pending Nasdaq listing approval

ADIAL PHARMACEUTICALS, INC.

Adial adjourned votes on Proposals 3, 4, 5 and 6 at its 2026 Annual Meeting because Nasdaq had not approved its Initial Listing Application.
The reconvened Oct. 1, 2026 meeting was further adjourned; polls remain open and the meeting will reconvene Oct. 15, 2026 at 8:30 a.m. ET.
The record date for the 2026 Annual Meeting remains Aug. 17, 2026, and stockholders who already voted on Proposals 3-6 need not act unless changing their vote.
Proposals 1, 2, 7, 8, 9, 10, 11 and 12 were voted on at the Sept. 17, 2026 meeting; the definitive proxy statement was filed Aug. 24, 2026.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.